These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6085475)

  • 21. Angiotensin converting enzyme inhibition: a new therapeutic modality.
    Gavras H; Charocopos F; Brunner H; Gavras I
    Bull N Y Acad Med; 1981 May; 57(4):304-10. PubMed ID: 6164426
    [No Abstract]   [Full Text] [Related]  

  • 22. Captopril, an orally active angiotensin I converting enzyme inhibitor in the treatment of renovascular and essential hypertension.
    Holtzman E; Rosenthal T; Stern N; Knecht A; Yaron A
    Isr J Med Sci; 1982 May; 18(5):597-602. PubMed ID: 6284678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vasoactive peptides and hypertension: role of angiotensin converting enzyme.
    Johnston CI; Iansek R; Millar JA; McGrath BP; Matthews PG
    Aust N Z J Med; 1981; 11(Suppl 1):59-63. PubMed ID: 6266379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. News about ACE, or, the separate lives of "Siamese twin" domains.
    Erdös EG
    J Clin Invest; 1996 Feb; 97(3):588. PubMed ID: 8609210
    [No Abstract]   [Full Text] [Related]  

  • 25. ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat.
    Sacco G; Mario B; Lopez G; Evangelista S; Manzini S; Maggi CA
    Vascul Pharmacol; 2009; 50(5-6):166-70. PubMed ID: 19344651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin converting enzyme inhibitors: drug interactions.
    Hodsman GP; Johnston CI
    J Hypertens; 1987 Feb; 5(1):1-6. PubMed ID: 3035008
    [No Abstract]   [Full Text] [Related]  

  • 27. Overview: the role of angiotensin-converting enzyme inhibitors in cardiovascular therapy.
    Abrams WB; Davies RO; Ferguson RK
    Fed Proc; 1984 Apr; 43(5):1314-21. PubMed ID: 6323221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical monitoring of vasoactive peptides during angiotensin converting enzyme inhibition.
    Giese J; Rasmussen S; Nielsen MD; Ibsen H
    J Hypertens Suppl; 1983 Oct; 1(1):31-6. PubMed ID: 6100607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increase in cyclic AMP levels and vasopressin release in response to angiotensin I in neurohypophyses: blockade following inhibition of the converting enzyme.
    Sirois P; Gagnon DJ
    J Neurochem; 1975 Nov; 25(5):727-9. PubMed ID: 172607
    [No Abstract]   [Full Text] [Related]  

  • 30. Inhibition of angiotensin converting enzyme from sheep tissues by captopril, lisinopril and enalapril.
    Udupa EG; Rao NM
    Indian J Biochem Biophys; 1997 Dec; 34(6):524-8. PubMed ID: 9594434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Converting enzyme inhibition: implications for renal perfusion and function.
    Hollenberg NK
    Clin Exp Pharmacol Physiol Suppl; 1982; 7():73-9. PubMed ID: 6183037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Converting-enzyme inhibition and glomerular filtration rate in essential hypertension.
    Bianchi MD; Fernandes M
    N Engl J Med; 1980 Jan; 302(3):179. PubMed ID: 6243169
    [No Abstract]   [Full Text] [Related]  

  • 33. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
    Ianzer D; Santos RA; Etelvino GM; Xavier CH; de Almeida Santos J; Mendes EP; Machado LT; Prezoto BC; Dive V; de Camargo AC
    J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of the effects of two angiotensin converting enzyme inhibitors, SQ 14 225 and MK 422 in Na-restricted sheep.
    Nelson MA; Stewart KW; Coghlan JP; Denton DA; Fei DT; Scoggins BA
    Clin Exp Pharmacol Physiol Suppl; 1982; 7():87-91. PubMed ID: 6183038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Captopril inhibits angiotensin converting enzyme. New principles for therapy in hypertension and heart failure].
    Ohman KP; Karlberg BE
    Lakartidningen; 1981 Nov; 78(45):4039-41. PubMed ID: 6276631
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of the inhibition of angiotensin converting enzyme on renin release mediated by exercise in man [proceedings].
    Khokhar AM; Havard CW; Slater JD
    J Endocrinol; 1979 Oct; 83(1):37P-38P. PubMed ID: 230274
    [No Abstract]   [Full Text] [Related]  

  • 37. [Effect of captopril on angiotensin-converting enzyme activity and animal behavior in the "open field" test].
    Vernigora AN; Gengin MT; Nikishin NN; Shchetinina NV
    Vopr Med Khim; 1996; 42(1):34-8. PubMed ID: 8999656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Converting enzyme activity in regulation of blood pressure and kidney function. A review.
    Piryova B; Girchev R
    Cor Vasa; 1984; 26(6):401-7. PubMed ID: 6098419
    [No Abstract]   [Full Text] [Related]  

  • 39. [Peptides--inhibitors of carboxycathepsin (peptidyl-dipeptidase A) and their role in clinical medicine].
    Orekhovich VN; Eliseeva IuE; Pavlikhina LV; Krit NA; Filatova MP
    Vopr Med Khim; 1984; 30(3):51-6. PubMed ID: 6206649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alteration of the granulomatous response in murine schistosomiasis by the chronic administration of captopril, an inhibitor of angiotensin-converting enzyme.
    Weinstock JV; Boros DL
    Gastroenterology; 1981 Nov; 81(5):953-8. PubMed ID: 6269948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.